There was an increasing trend in ADR reporting every year for all five ADs with peaks in 2014 ( Figure 1 ).
← all excerpts
A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.
1
—
—